Pfizer has announced a substantial agreement with Metsera, a biotechnology company founded in 2022, involving a $7.3 billion investment. Metsera’s pipeline encompasses both oral and injectable medications targeting multiple pathways involved in obesity. The agreement signifies a strategic expansion for Pfizer’s oncology and metabolic drug development efforts. Specifically, the investment focuses on enhancing the efficacy and patient accessibility of Metsera’s existing treatments. Pfizer anticipates leveraging this partnership to bolster its pipeline and potentially introduce new obesity medications in the future.
Credits: US Top News and Analysis
